Transplantation in an evolving therapy landscape

Novartis supported Industry Symposium (Hall A)

Saturday, October 26


Prof. Dr. Nicolaus Kröger
Controversial situations in FLT3-mutated AML patients
Prof. Dr. Lars Bullinger
JAK Inhibition for GvHD
Prof. Dr. Nicolaus Kröger
How to place CAR-T in r/r pedALL treatment algorithm
Prof. Dr. Peter Bader
Prof. Dr. med. Peter Bader
Head of the Division for Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital of Frankfurt
Prof. Dr. med. Lars Bullinger
Director, Division of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum Charité – Universitätsmedizin, Berlin
Prof. Dr. med. Nicolaus Kröger
Head of the Department for Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf
Novartis Pharma GmbH
Roonstraße 25
90429 Nürnberg

© The International Congress on Controversies in Stem Cell and Cellular Therapies (COSTEM).

Tel: +44 20 3289 9552